Promising small molecule for heart failure targeting adrenal catecholamine release and β-adrenergic receptor signaling in the heart.
Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota; Division of Cardiology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota. Electronic address: jlhall@umn.edu.
Jennifer L
JL
Hall
Department of Integrative Physiology, University of Minnesota, Minneapolis, Minnesota.
Timothy D
TD
O'Connell
Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota; Division of Cardiology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Gary S
GS
Francis
D000311:Adrenal Glands / Q000378:metabolism*; D000818:Animals; D054769:G-Protein-Coupled Receptor Kinase 2 / Q000037:antagonists & inhibitors*; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D014966:Xanthenes / Q000627:therapeutic use*
D014966:Xanthenes; C007820:gallein; D054769:G-Protein-Coupled Receptor Kinase 2
catecholamines; heart failure; mice; small molecules; transverse aortic constriction; α(2)-adrenergic receptor; β-adrenergic receptor